

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **Lansen Pharmaceutical Holdings Limited**

朗生醫藥控股有限公司

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 503)**

### **CHANGE OF COMPANY SECRETARY, CHIEF FINANCIAL OFFICER AND AUTHORIZED REPRESENTATIVE**

The Board announces that Mr. Chan Sheung Chi resigned as Company Secretary, authorized representative and Chief Financial Officer of the Company with effect from 25 September 2010.

Ms. Yip Pui Ling, Rebecca has been appointed as acting Company Secretary and Chief Financial Officer of the Company, and Ms. Poon Lei Yung has been appointed as acting authorized representative of the Company, both with effect from 25 September 2010.

The board of directors (the “**Board**”) of Lansen Pharmaceutical Holdings Limited (the “**Company**”) announces that Mr. Chan Sheung Chi (“**Mr. Chan**”) resigned as Company Secretary, Chief Financial Officer and one of the authorized representatives of the Company, for the purpose of Rule 3.05 of the Rules Governing the Listing of Securities (the “**Listing Rules**”) on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and Part XI of the Hong Kong Companies Ordinance with effect from 25 September 2010, as he has to pursue his other career opportunities. Mr. Chan confirmed that he has no disagreement with the Board and there is no other matter in relation to his resignation that needs to be brought to the attention of the shareholders of the Company or the Stock Exchange.

The Company is actively identifying suitable candidates with appropriate qualifications to fill the vacancy of Company Secretary, Chief Financial Officer and authorized representative in compliance with the requirements of the Listing Rules. In the interim period, Ms. Yip Pui Ling, Rebecca, one of the non-executive directors of the Company, has been appointed as acting Company Secretary and Chief Financial Officer of the Company, and Ms. Poon Lei Yung, the senior vice president of the Company, has been

appointed as acting authorized representative of the Company, both appointments with effect from 25 September 2010.

The Board takes this opportunity to thank Mr. Chan for his valuable contribution during his tenure of services with the Company and wish him all the best in his new career pursuit.

By Order of the Board  
**Lansen Pharmaceutical Holdings Limited**  
**Stephen Burnau Hunt**  
*Chairman*

Hong Kong, 22 September 2010

*As at the date of this announcement, the Company has two executive Directors, five non-executive Director and three independent non-executive Directors. The executive Directors are Mr. Xu Jun and Mr. Liu Xiao Dong. The non-executive Directors are Mr. Stephen Burnau Hunt, Mr. Lee Jin Yi, Mr. Tang Jun, Ms. Tao Fang Fang and Ms. Yip Pui Ling, Rebecca. The independent non-executive Directors are Mr. Robert Peter Thian, Mr. Chan Kee Huen, Michael and Mr. Tang Chiu Ping, Raymond.*